MDxHealth SA MDXH

What this company does

MDxHealth SA's core menu of testing solutions includes Confirm mdx for Prostate Cancer, Genomic Prostate Score (GPS mdx), and ExoDx Prostate Test (Exo mdx), which provide DNA and RNA insights to physicians and patients regarding urologic disease and treatment options. Its Exo mdx test is a noninvasive urine test, requiring no digital rectal exam, with a 91% negative predictive value for clinically significant prostate cancer, and is used to help physicians determine whether a biopsy is advisable when a patient presents with an elevated PSA level or an abnormal DRE result. For men who proceed to a biopsy, its Confirm mdx test measures biomarker signals in the biopsied tissue and provides physicians with a 96% negative predictive value for clinically significant disease. Upon diagnosis of localized prostate cancer, its GPS mdx test measures the expression of a panel of genes in prostate cancer tissue to predict the likelihood of adverse pathology, risk of metastasis, and prostate cancer death. More than 7,000 urologists have ordered over 500,000 of the company's tests. The company processes its tests and conducts research and development at a 49,000-square-foot headquarters and laboratory facility in Irvine, California, and also maintains laboratory facilities of 8,000 square feet in Plano, Texas and 23,600 square feet in Waltham, Massachusetts. MDxHealth SA was incorporated on January 10, 2003 as a company with limited liability under the laws of Belgium.

Written from the business description in MDxHealth SA's annual report to the U.S. Securities and Exchange Commission, filed 3 April 2026. Every sentence was checked against that document before publication.